Vaccinex Inc
Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat cancer, neurodegenerative diseases, and autoimmune disorders. The company's lead drug candidate, pepinemab, a humanized monoclonal antibody that binds and blocks the activity of SEMA4D. It is developing Pepinemab, which is in phase 2 study for treatment of Alzheime… Read more
Vaccinex Inc (VCNX) - Total Assets
Latest total assets as of September 2024: $4.85 Million USD
Based on the latest financial reports, Vaccinex Inc (VCNX) holds total assets worth $4.85 Million USD as of September 2024.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Vaccinex Inc - Total Assets Trend (2016–2023)
This chart illustrates how Vaccinex Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Vaccinex Inc - Asset Composition Analysis
Current Asset Composition (December 2023)
Vaccinex Inc's total assets of $4.85 Million consist of 92.2% current assets and 7.8% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 42.3% |
| Accounts Receivable | $961.00K | 26.5% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2016–2023)
This chart illustrates how Vaccinex Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Vaccinex Inc's current assets represent 92.2% of total assets in 2023, an increase from 74.3% in 2016.
- Cash Position: Cash and equivalents constituted 42.3% of total assets in 2023, down from 58.4% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2016.
- Asset Diversification: The largest asset category is accounts receivable at 26.5% of total assets.
Vaccinex Inc Competitors by Total Assets
Key competitors of Vaccinex Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
ESSA Pharma Inc
NASDAQ:EPIX
|
USA | $110.50 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Vaccinex Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Vaccinex Inc generates 0.16x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Vaccinex Inc is currently not profitable relative to its asset base.
Vaccinex Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.77 | 0.35 | 0.58 |
| Quick Ratio | 0.77 | 0.35 | 0.58 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-1.42 Million | $ -4.16 Million | $ -2.87 Million |
Vaccinex Inc - Advanced Valuation Insights
This section examines the relationship between Vaccinex Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 7.34 |
| Latest Market Cap to Assets Ratio | 0.31 |
| Asset Growth Rate (YoY) | -54.5% |
| Total Assets | $3.63 Million |
| Market Capitalization | $1.12 Million USD |
Valuation Analysis
Below Book Valuation: The market values Vaccinex Inc's assets below their book value (0.31 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Vaccinex Inc's assets decreased by 54.5% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Vaccinex Inc (2016–2023)
The table below shows the annual total assets of Vaccinex Inc from 2016 to 2023.
| Year | Total Assets | Change |
|---|---|---|
| 2023-12-31 | $3.63 Million | -54.48% |
| 2022-12-31 | $7.98 Million | -18.96% |
| 2021-12-31 | $9.84 Million | -15.89% |
| 2020-12-31 | $11.70 Million | +154.17% |
| 2019-12-31 | $4.60 Million | -79.10% |
| 2018-12-31 | $22.03 Million | +295.12% |
| 2017-12-31 | $5.58 Million | +96.16% |
| 2016-12-31 | $2.84 Million | -- |